254 related articles for article (PubMed ID: 31567439)
1. Updates on intravesical therapy.
Pisano F; Vila Reyes H; Breda A; Palou J
Curr Opin Urol; 2019 Nov; 29(6):649-655. PubMed ID: 31567439
[TBL] [Abstract][Full Text] [Related]
2. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer.
Hendricksen K; Witjes JA
Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630
[TBL] [Abstract][Full Text] [Related]
3. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
4. Intravesical therapy for bladder cancer.
Williams SK; Hoenig DM; Ghavamian R; Soloway M
Expert Opin Pharmacother; 2010 Apr; 11(6):947-58. PubMed ID: 20205607
[TBL] [Abstract][Full Text] [Related]
5. What to do during Bacillus Calmette-Guérin shortage? Valid strategies based on evidence.
Abufaraj M; Mostafid H; Shariat SF; Babjuk M
Curr Opin Urol; 2018 Nov; 28(6):570-576. PubMed ID: 30138122
[TBL] [Abstract][Full Text] [Related]
6. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
7. Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancer.
Crijnen J; De Reijke TM
Expert Opin Emerg Drugs; 2018 Jun; 23(2):135-147. PubMed ID: 29730950
[TBL] [Abstract][Full Text] [Related]
8. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
Turker P; Turkeri L
Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
[TBL] [Abstract][Full Text] [Related]
9. Bladder-preserving strategies for Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer; where are we and what will be expected?
Sari Motlagh R; Pradere B; Mori K; Miura N; Abufaraj M; Shariat SF
Curr Opin Urol; 2020 Jul; 30(4):584-593. PubMed ID: 32304379
[TBL] [Abstract][Full Text] [Related]
10. Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study.
Oughton JB; Poad H; Twiddy M; Collinson M; Hiley V; Gordon K; Johnson M; Jain S; Noon AP; Chahal R; Simms M; Dooldeniya M; Koenig P; Goodwin L; Brown JM; Catto JWF;
BMJ Open; 2017 Aug; 7(8):e017913. PubMed ID: 28801444
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis of and therapy for non-muscle-invasive bladder cancer - state of the art].
Kausch von Schmeling I
Aktuelle Urol; 2010 Sep; 41(5):307-15. PubMed ID: 20824576
[TBL] [Abstract][Full Text] [Related]
12. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy.
Barlow LJ; McKiernan JM; Benson MC
J Urol; 2013 Mar; 189(3):834-9. PubMed ID: 23123371
[TBL] [Abstract][Full Text] [Related]
13. Tissue biomarkers in nonmuscle-invasive bladder cancer: any role in clinical practice?
Bruchbacher A; Soria F; Hassler M; Shariat SF; D'Andrea D
Curr Opin Urol; 2018 Nov; 28(6):584-590. PubMed ID: 30188332
[TBL] [Abstract][Full Text] [Related]
14. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
Lammers RJ; Witjes JA
Expert Rev Anticancer Ther; 2010 Dec; 10(12):1903-16. PubMed ID: 21110757
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Intravesical Bacillus Calmette-Guérin Immunotherapy in Patients with Non-Muscle-Invasive Bladder Cancer Presenting with Asymptomatic Bacteriuria: A Systematic Review.
Poletajew S; Zapała P; Radziszewski P
Urol Int; 2017; 99(1):1-5. PubMed ID: 28601885
[TBL] [Abstract][Full Text] [Related]
16. Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.
Khaled D; Taylor J; Holzbeierlein J
Urol Clin North Am; 2020 Feb; 47(1):119-128. PubMed ID: 31757295
[TBL] [Abstract][Full Text] [Related]
17. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of combined intravesical immunotherapy and chemotherapy for non-muscle invasive bladder cancer.
Hilton WM; Ercole B; Parekh DJ; Sonpavde G; Ghosh R; Svatek RS
Expert Rev Anticancer Ther; 2011 Jun; 11(6):949-57. PubMed ID: 21707292
[TBL] [Abstract][Full Text] [Related]
19. Emerging Immunotherapy Options for bacillus Calmette-Guérin Unresponsive Nonmuscle Invasive Bladder Cancer.
Meng MV; Gschwend JE; Shore N; Grossfeld GD; Mostafid H; Black PC
J Urol; 2019 Dec; 202(6):1111-1119. PubMed ID: 31042108
[TBL] [Abstract][Full Text] [Related]
20. Bladder Cancer: A Review.
Lenis AT; Lec PM; Chamie K; Mshs MD
JAMA; 2020 Nov; 324(19):1980-1991. PubMed ID: 33201207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]